2025 ACR Guideline for SLE: Steroid-Sparing Blueprint
Key Questions
What are the main recommendations in the 2025 ACR SLE guidelines?
The guidelines emphasize steroid minimization, universal lifelong hydroxychloroquine (HCQ) use, and early escalation to biologics. They align with EULAR/NICE recommendations for lupus nephritis and proactive management using pipelines like BTK/TLR inhibitors.
Why does the 2025 ACR guideline focus on steroid-sparing strategies?
Steroid minimization reduces prolonged glucocorticoid exposure risks, supported by Rheum Advocate strategies and AbbVie long-term data. It promotes a blueprint for safer lupus care through tapering tips.
What is the role of hydroxychloroquine (HCQ) in the new guidelines?
Universal lifelong HCQ is recommended, with optimization based on actual body weight for better efficacy in SLE. Timing and dosing tips, like those for Plaquenil, enhance its benefits.
How do the 2025 ACR guidelines address biologic therapies?
They advocate early biologic escalation for proactive lupus management. This aligns with emerging BTK/TLR inhibitors and data from lupus nephritis recommendations.
What additional tips does the Rheum Advocate provide for lupus care?
Rheum Advocate offers strategies for appropriate HCQ use, reducing glucocorticoid exposure, and capturing patient-reported physical function. These complement the 2025 ACR guideline's steroid-sparing focus.
New 2025 ACR SLE guidelines emphasize steroid minimization, universal lifelong HCQ, and early biologic escalation, aligning with EULAR/NICE LN recs, AbbVie LT data, and emerging pipelines like BTK/TLR inhibitors for proactive lupus management; Rheum Advocate adds HCQ optimization and GC taper tips.